CTXR vs. ALLK, CUE, PMVP, ASRT, GNLX, RLMD, RZLT, IOBT, OPTN, and CLRB
Should you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Allakos (ALLK), Cue Biopharma (CUE), PMV Pharmaceuticals (PMVP), Assertio (ASRT), Genelux (GNLX), Relmada Therapeutics (RLMD), Rezolute (RZLT), IO Biotech (IOBT), OptiNose (OPTN), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical preparations" industry.
Citius Pharmaceuticals (NASDAQ:CTXR) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.
Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks.
In the previous week, Citius Pharmaceuticals had 3 more articles in the media than Allakos. MarketBeat recorded 4 mentions for Citius Pharmaceuticals and 1 mentions for Allakos. Citius Pharmaceuticals' average media sentiment score of 0.68 beat Allakos' score of 0.06 indicating that Citius Pharmaceuticals is being referred to more favorably in the media.
Citius Pharmaceuticals has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Allakos has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.
Citius Pharmaceuticals received 25 more outperform votes than Allakos when rated by MarketBeat users. Likewise, 62.05% of users gave Citius Pharmaceuticals an outperform vote while only 59.34% of users gave Allakos an outperform vote.
Citius Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 516.90%. Allakos has a consensus price target of $1.83, indicating a potential upside of 27.31%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Citius Pharmaceuticals is more favorable than Allakos.
16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.6% of Allakos shares are owned by institutional investors. 15.0% of Citius Pharmaceuticals shares are owned by company insiders. Comparatively, 16.1% of Allakos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Citius Pharmaceuticals' return on equity of -40.78% beat Allakos' return on equity.
Summary
Citius Pharmaceuticals beats Allakos on 11 of the 15 factors compared between the two stocks.
Get Citius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Citius Pharmaceuticals Competitors List
Related Companies and Tools
